**Core tip:** Previously reported cases of interstitial lung and liver disease (ILLD) were associated with biallelic missense mutations in the methionyl-tRNA synthetase (*MARS*) gene. Here, we report a Chinese infant with typical ILLD (failure to thrive, developmental delay, interstitial lung disease, cholestasis, hepatomegaly, steatosis, anemia, and thrombocytosis) with novel phenotypes, such as kidney stones, acetabular dysplasia, prolonged fever, and extreme leukocytosis. Whole exome sequencing revealed a novel truncating variant (c.2158C\>T/p.Gln720Stop), and a novel tri-nucleotide insertion (c.893_894insTCG) in the *MARS* gene. Despite the resolution of cholestasis, this patient died of respiratory failure at the age of 11 mo.

INTRODUCTION
============

The methionyl-tRNA synthetase (*MARS*) gene encodes cytoplasmic methionyl-tRNA synthetase (MetRS) responsible for catalyzing the ligation of methionine to tRNA\[[@B1]\]. MetRS belongs to a family of aminoacyl-tRNA synthetases that play critical roles in protein biosynthesis by charging tRNAs with their cognate amino acids\[[@B2]\]. Interstitial lung and liver disease (ILLD) (OMIM\#615486) is caused by homozygous or compound heterozygous mutations in the *MARS* gene (156560) on chromosome 12q13\[[@B3]-[@B5]\]. Heterozygous *MARS* mutations have been reported to be associated with autosomal dominant Charcot-Marie-Tooth disease (CMT)\[[@B6]-[@B9]\]. The same *MARS* mutation may cause both ILLD and CMT\[[@B10]\]. *MARS* is also a candidate gene for hereditary spastic paraplegias (HSPs), a neuro-degenerative motor neuron disorder\[[@B11]\]. To date, no genetic changes other than missense variants have been reported in the literature. Here, we report a Chinese infant with lethal ILLD showing novel phenotypes such as kidney stones, acetabular dysplasia, prolonged fever, and extreme leukocytosis. Whole exome sequencing revealed a novel truncating variant together with a novel tri-nucleotide insertion in the *MARS* gene.

CASE REPORT
===========

A five-month old female infant was presented with a failure to thrive, developmental delay, jaundice, and dark urine. She was born full-term with a normal birth weight (3100 g) after an uncomplicated first pregnancy and vaginal delivery. Weight gain and developmental milestones were normal until three months of age (weighted 6000 g), when she failed to thrive with a body weight of 5700 g at the age of 5 mo without the ability of rolling over.

At in-patient admission, this patient was 5.2 mo old with a body weight of 5500 g (2^nd^ percentile by WHO standards), length of 55 cm (lower than the 1^st^ percentile), and head circumference of 39 cm (2^nd^ percentile). This infant had prolonged low-grade fever, pulmonary effusion, diffuse interstitial lung disease, significant leukocytosis, high procalcitonin (PCT)/CRP levels, and required nasal oxygen therapy. Serial chest X-rays showed some improvement in pulmonary effusion, but no improvement in interstitial lung involvement (Figure [1A](#F1){ref-type="fig"}). After serial antibiotic treatments (ceftriaxone, cefoperazone + slubactam, meropenem, norvancomycin, and fluconazole), body temperature was normalized, oxygen therapy was no longer needed, and leukocytosis improved, however the interstitial lung disease stayed the same. After treatment with ursodeoxycholic acid and fat-soluble vitamins, cholestasis improved significantly (Table [1](#T1){ref-type="table"}).

###### 

Changes in complete blood count, procalcitonin, serum biochemistry, and blood coagulation profiles

  **Age (mo) (^1^in-patient admission; ^2^discharge to out-patient follow-up)**   **5.1**                                               **5.6^1^**   **6**   **6.2**   **6.5**   **6.8**   **7**   **7.2^2^**   **9.5**   
  ------------------------------------------------------------------------------- ----------------------------------------------------- ------------ ------- --------- --------- --------- ------- ------------ --------- ------
  Complete blood count (reference range)                                          White blood cell (4-10 × 10^9^/L)                     16.9         21.1    71.7      26.4      33.7      45.8    30.3         24.3      14.3
  Neutrophil (20%-50%)                                                            58.1                                                  39.8         58.0    63.1      62.0      63.0      62.7    64.4         38.9      
  Lymphocyte (45%-75%)                                                            36.2                                                  53.1         31.1    28.7      28.9      15.0      29.5    27.8         51.4      
  Abnormal lymphocytes (0%)                                                       NA                                                    0.0          0.0     NA        0.0       17.0      0.0     0.0          NA        
  Platelet count (100-300 × 10^9^/L)                                              764.0                                                 513.0        993.0   464       387.0     494.0     279.0   397          386.0     
  Hemoglobin (110-160 g/L)                                                        78.0                                                  85.2         78.2    60.1      64.0      65.2      90.0    88.0         122.0     
  Red blood cell count (4.0-5.5 × 10^12^ /L)                                      3.5                                                   3.1          2.8     2.0       2.0       2.2       2.9     2.9          4.3       
  Reticulocyte (0.5%-1.5%)                                                        NA                                                    2.9          6.7     NA        6.3       7.8       3.3     6.8          1.0       
  C-reactive protein (\< 8 mg/L)                                                  1.0                                                   8.0          90.0    32.0      43.0      37.0      45.0    8.0          8.0       
  Procalcitonin (\< 0.05 ng/mL)                                                   NA                                                    4.6          17.4    7.7       13.4      NA        NA      NA           NA        
  Serum biochemistry (reference range)                                            Albumin (35-55 g/L)                                   29.0         34.6    27.3      30.8      32.3      28.7    38.5         39.1      43.0
  Alanine aminotransferase (0-40 IU/L)                                            41.0                                                  45.0         17.0    13.0      4.0       50.0      49.0    38.0         29.0      
  Aspartate aminotransferase (0-40 IU/L)                                          100.0                                                 104.0        46.0    37.0      66.0      98.0      70.0    62.0         41.0      
  Total bilirubin (5.1-17.1 μmol/L)                                               68.0                                                  120.4        133.0   132.9     126.8     110.6     90.1    42.9         8.1       
  Direct bilirubin (0-6 μmol/L)                                                   53.0                                                  76.9         93.7    96.1      86.6      70.4      61.8    29.8         4.4       
  γ-glutamyl transferase (7-50 IU/L)                                              73.0                                                  61.0         76.0    58.0      54.0      57.0      107.0   230.0        122.0     
  Total bile acid (0-10 μmol/L)                                                   NA                                                    182.8        123.3   152.4     137.2     157.4     311.7   282.3        34.6      
  Alkaline phosphatase (42-383 IU/L)                                              307.0                                                 137.0        149.0   119.0     122.0     148.0     178.0   214.0        378.0     
  Blood glucose (3.9-5.8 mmol/L)                                                  NA                                                    1.2          1.6     8.4       1.1       NA        NA      3.6          NA        
  Lactic acid (0-2 mmol/L)                                                        NA                                                    3.9          NA      3.6       3.6       NA        NA      NA           NA        
  Ammonia (10-47 μmol/L)                                                          NA                                                    88.0         NA      NA        NA        NA        NA      55.0         NA        
  Total cholesterol (3.1-5.2 mmol/L)                                              3.1                                                   2.0          NA      2.3       2.5       NA        2.8     4.4          3.1       
  LDL-cholesterol (1.30-3.90 mmol/L)                                              NA                                                    NA           NA      1.0       NA        NA        NA      NA           NA        
  HDL-cholesterol (0.91-2.05 mmol/L)                                              NA                                                    NA           NA      0.3       NA        NA        NA      NA           NA        
  Triglyceride (0.56-1.70 mmol/L)                                                 NA                                                    2.0          NA      2.7       2.1       NA        2.1     1.8          1.5       
  Blood coagulation profiles (reference range)                                    Activated partial thromboplastin time (28.0-44.5 s)   NA           48.1    NA        57.5      56.4      53.9    47.7         42.3      43.8
  D-dimer (0-0.3 mg/L)                                                            NA                                                    0.94         NA      2.06      1.15      0.97      0.7     0.51         NA        
  Fibrinogen (2-4 g/L)                                                            NA                                                    1.45         NA      1.82      2.29      2.54      3.03    3.46         3.44      
  Fibrinogen degradation products (0-5 μg/ML)                                     NA                                                    1.31         NA      5.22      2.35      2.78      1.47    1.16         NA        
  Thrombin time (14-21 s)                                                         NA                                                    20.4         NA      19.1      19.9      19.9      15.8    18.4         15.2      
  International normalized ratio (0.8-1.2)                                        NA                                                    NA           NA      1.29      1.26      1.35      1.3     1.03         0.99      
  Prothrombin time (12.0-14.8 s)                                                  NA                                                    NA           NA      16        15.7      16.5      16.1    13.5         13.1      
  Prothrombin time activity (80%-100%)                                            NA                                                    NA           NA      67        69        63        66      95           103       

NA: Not available.

![Imaging and histopathological features. A: Contrast enhanced pulmonary CT scan (1-3), and chest X-ray (4) showing pulmonary effusion with marked interstitial lung involvement; B: Hyper-echoic lesions consistent with stone formation on ultrasonography (arrows; 1, right kidney; 2, left kidney) and non-contrast abdominal computed tomography scan (arrow, 3). Acetabular dysplasia (4, arrowhead showing abnormally shallow hip socket); C: Liver biopsy (all originally magnified principal images): severe steatosis of hepatic cells with ballooning, lobular disarray, and cholestasis (1-4), mild fibrosis (5), mild lymphocyte infiltration (4), bile duct proliferation (6 CK-7, 7 CK-19), and hepatic iron deposition (8). *MARS* immunohistochemistry staining, coarsely granular pigments within the cytoplasm in the index patient (9), but not in samples of a healthy control (10). *MARS*: Methionyl-tRNA synthetase gene.](WJG-24-4208-g001){#F1}

The patient was discharged with normal oxygen saturation on room air without apparent respiratory distress or cough. A liver function test and complete blood count were normal at a 9.5 mo follow-up. However, the infant was admitted to a provincial level pediatric intensive care unit for acute respiratory distress at 11 mo of age and received mechanical ventilation. Despite treatment, she died of respiratory failure and hypoxic encephalopathy.

A genetic cause was suspected due to multiple system involvement, although a liver panel consisting of 41 genes (Table [2](#T2){ref-type="table"}) related to liver diseases came back negative. Lysosomal storage disease was considered, but an enzyme panel for the screening of common lysosomal storage diseases was normal, as was the urine acidoglycoprotein level. This patient was enrolled for the undiagnosed disease patient program in our hospital, and whole exome sequencing was ordered. Compound heterozygous *MARS* gene variants, c.2158C\>T/p.Gln720Stop and c.893_894insTCG/p.Arg299dup, were detected. Presence of these mutations was confirmed with Sanger sequencing, and parental origins were ascertained. Both variants were not reported in the dbSNP137 ([http://www. ncbi.nlm.nih.gov/snp/](http://www. ncbi.nlm.nih.gov/snp/)), 1000 Genome Database (<http://www.1000genomes.org/>), and Exome Variant Server (<http://evs.gs.washington.edu/EVS/>). The c.2158C\>T mutation was inherited from the healthy mother, which caused the change of a glutamine amino acid at position 720 to a stop codon, which was predicted to be disease-causing by MutationTaster (<http://www.mutationtaster.org>). The tri-nucleotide insertion (c.893_894insTCG) inherited from her healthy father caused the insertion of a single amino acid (arginine) at position 299, which was predicted to be disease-causing by MutationTaster (Figure [2A](#F2){ref-type="fig"}). The detailed genetic testing results and secondary findings are provided in Table [2](#T2){ref-type="table"}.

###### 

Genetic testing results

  **Genetic Tests**                             **Gene**        **Transcript ID**                                                                                                                                                                                                                                                                                **Associated conditions (Inheritance patterns) in OMIM**                                                                                                   **Variant**       **Amino-acid change**   **Hom/Het**   **Parental origin**   **Prediction of pathogenicity**                                     
  --------------------------------------------- --------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- ----------------------- ------------- --------------------- --------------------------------- ------------- ------------------- --------
  Liver Panel[1](#T2FN1){ref-type="table-fn"}   *ATP8B1*        NM \_005603                                                                                                                                                                                                                                                                                      Cholestasis, benign recurrent, intrahepatic (AR); cholestasis, intrahepatic, of pregnancy, 1 (AD); cholestasis, progressive familial intrahepatic 1 (AR)   c.234C\> G        p.His78Gln              Het           NA                    Polymorphism                      Tolerated     Neutral             Benign
  c.1729A\>G                                    p.Ile577Val     Het                                                                                                                                                                                                                                                                                              NA                                                                                                                                                         Polymorphism      Tolerated               Neutral       Possibly damaging                                                                         
  c.2021T\>C                                    p\. Met674Thr   Het                                                                                                                                                                                                                                                                                              NA                                                                                                                                                         Polymorphism      Tolerated               Neutral       Benign                                                                                    
  c.3477C\>T                                    Synonymous      Het                                                                                                                                                                                                                                                                                              NA                                                                                                                                                         Polymorphism      Tolerated               Neutral       NA                                                                                        
  c.3744C\>A                                    Synonymous      Het                                                                                                                                                                                                                                                                                              NA                                                                                                                                                         Polymorphism      Tolerated               Neutral       NA                                                                                        
  Whole exome sequencing                        *MARS*          NM_004990                                                                                                                                                                                                                                                                                        Charcot-Marie-Tooth disease, axonal, type 2U (AD); Interstitial lung and liver disease (AR)                                                                c.2158C\>T        p.Gln720Stop            Het           Maternal              Disease causing                   NA            NA                  NA
  c.893_894insTCG                               p.Arg299dup     Het                                                                                                                                                                                                                                                                                              Paternal                                                                                                                                                   Disease causing   NA                      Deleterious   NA                                                                                        
  *ATP8B1*                                      NM_005603       Cholestasis, benign recurrent, intrahepatic (AR); cholestasis, intrahepatic, of pregnancy, 1 (AD); cholestasis, progressive familial intrahepatic 1 (AR)                                                                                                                                         c.2021T\>C                                                                                                                                                 p\. Met674Thr     Het                     Paternal      polymorphism          Tolerated                         Neutral       Benign              
  *CPT1A*                                       NM_001876       CPT deficiency, hepatic, type IA (AR)                                                                                                                                                                                                                                                            c.1163+5G\>A                                                                                                                                               \-                Het                     Maternal      Disease causing       NA                                NA            NA                  
  *LRPPRC*                                      NM_133259       Leigh syndrome, French-Canadian type (AR)                                                                                                                                                                                                                                                        c.2965C\>T                                                                                                                                                 p.Arg989Cys       Het                     Maternal      Disease causing       Damaging                          Deleterious   Probably damaging   
  *FLG*                                         NM_002106       Ichthyosis vulgaris (AD); (Dermatitis, atopic, susceptibility to, 2)                                                                                                                                                                                                                             c.5841G\>A                                                                                                                                                 p.Trp1947Stop     Het                     Maternal      Disease causing       NA                                NA            NA                  
  *G6PD*                                        NM_00104251     Hemolytic anemia, G6PD deficient (favism) (XLD); (Resistance to malaria due to G6PD deficiency)                                                                                                                                                                                                  c.241C\>T                                                                                                                                                  p.Arg81Cys        Het                     Maternal      Disease causing       Damaging                          Deleterious   Benign              
  *POMGNT1*                                     NM_017739       Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 3 (AR); Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 3 (AR); Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 3 (AR); Retinitis pigmentosa 76 (AR)   c.794G\>A                                                                                                                                                  p.Arg265His       Het                     Maternal      Disease causing       Damaging                          Deleterious   Probably damaging   
  *SERPINC1*                                    NM_000488       Thrombophilia due to antithrombin III deficiency (AD/AR)                                                                                                                                                                                                                                         c.719A\>G                                                                                                                                                  p.Asn240Ser       Het                     Maternal      Polymorphism          Tolerated                         Neutral       Benign              
  *TG*                                          NM_003235       Thyroid dyshormonogenesis 3 (AR); (autoimmune thyroid disease, susceptibility to, 3)                                                                                                                                                                                                             c.5791A\>G                                                                                                                                                 p.Ile1931Val      Het                     Paternal      Polymorphism          Tolerated                         Neutral       Benign              
  *USH2A*                                       NM_206933       Retinitis pigmentosa 39; Usher syndrome type 2A (AR)                                                                                                                                                                                                                                             c.8559-2A\>G                                                                                                                                               \-                Het                     Paternal      Disease causing       NA                                NA            NA                  

Genes included in liver panel: *ATP8B1, ABCB11, ABCB4, TJP2, BAAT, CLDN1, HSD3B7, AKR1D1, CYP7B1, AMACR, CYP27A1, DHCR7, JAG1, NOTCH2, SLC25A13, DGUOK, MPV17, FAH, ABCC2, UGT1A1, NPC1, NPC2, GALT, GALE, ALDOA, ALDOB, KRT18, KRT8, CIRH1A, CFTR, GFDM1, EARS2, HSD17B4, LIPA, PEX1, PEX5, POU1F1, HESX1, SERPINA1, VIPAS39*, and *VPS33B*. NA: Not available.

![Genetic testing results, protein features, and distribution of reported variants within the methionyl-tRNA synthetase protein. A: Sanger sequencing confirmation of the index case and parents, both variants affect highly conserved amino acid residues of the MetRS protein; B: Illustration of MetRS protein domains, location of amino acid changes of the reported variants so far. ^1^Variants from our report; ^2^Variants from Chinese ILLD cases. MetRS: Methionyl-tRNA synthetase; ILLD: Interstitial lung and liver disease.](WJG-24-4208-g002){#F2}

Liver biopsy results showed severe steatosis of hepatic cells with ballooning, lobular disarray, and cholestasis. Mild changes, such as fibrosis, lymphocyte infiltration, and bile duct proliferation, were seen within the portal region. Hepatic iron deposition was seen after iron staining, but copper staining was negative (Figure [1C](#F1){ref-type="fig"}). Sinosoids and Kupffer cells seemed normal. Immunohistochemical staining for hepatitis B surface antigen, core antigen, Epstein-Barr virus, and langerin cells were negative. Immunohistochemical staining for cholestasis-related proteins, such as BSEP, MDR3, MRP2, TJP2, and MYO5B, were all normal. After genetic diagnosis, we used a rabbit anti-MARS monoclonal antibody (purchased from <http://www.abcam.cn>, product code: ab180497) to perform immunohistochemical staining on paraffin-embedded liver biopsy samples. When compared to a normal liver sample (donated for liver transplantation), coarsely granular pigments within the cytoplasm were seen in the index patient sample.

Ultrasound examination revealed marked hepatomegaly (liver 4 cm below the right costal margin, and 5 cm below the xiphoid process) and reduced hepatic echogenicity. Hyper-echoic lesions consistent with stone formation were seen on both kidneys. Abdominal computed tomography scans showed hepatic steatosis and hyper-echoic lesions suggestive of kidney stones in the left kidney but not in the right kidney (Figure [1B](#F1){ref-type="fig"}). X-ray imaging of the skull was normal, as were the long bones of both arms and legs. X-ray imaging also picked up abnormally shallow hip sockets on both sides, which is suggestive of acetabular dysplasia or congenital hip dysplasia (Figure [1B](#F1){ref-type="fig"}). Other diagnostic evaluations are provided in Table [3](#T3){ref-type="table"}.

###### 

Diagnostic evaluation of the patient with a methionyl-tRNA synthetase mutation

  **Etiological assessment**                                                                                                                                                                                                                                                                               **Investigations performed (normal unless otherwise indicated)**
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Infections                                                                                                                                                                                                                                                                                               Serum procalcitonin levels (significantly elevated, Table [1](#T1){ref-type="table"});
  Serology for Hepatitis B, C, HIV, syphilis, EBV, CMV, HSV, toxoplasmin, and rubella virus;                                                                                                                                                                                                               
  PCR for CMV; beta-d-glucan assay; galactomannan assay; T-Spot.TB test;                                                                                                                                                                                                                                   
  Cerebrospinal fluid analysis for white blood cell count, protein, and glucose level;                                                                                                                                                                                                                     
  Complete blood count: anemia, elevated WBC and C-reactive protein (Table [1](#T1){ref-type="table"});                                                                                                                                                                                                    
  Culture for blood, urine, sputum, alveolar lavage fluid, and cerebrospinal fluid;                                                                                                                                                                                                                        
  Sputum and alveolar lavage fluid for mycoplasma/chlamydia DNA detection;                                                                                                                                                                                                                                 
  Sputum and alveolar lavage fluid for detection of respiratory syncytial virus, adenovirus, influenza virus, and para-influenza virus antigens;                                                                                                                                                           
  Alveolar lavage fluid smear for fungus detection                                                                                                                                                                                                                                                         
  Radiology, endoscopy, and histopathology                                                                                                                                                                                                                                                                 Multiple chest X-rays and a contrast-enhanced computed tomography scan of the lung (alveolar effusions with severe interstitial lung disease) (Figure [1](#F1){ref-type="fig"});
  Abdominal ultrasonography and CT scan (hepatomegaly, liver steatosis, kidney stones) (Figure [1](#F1){ref-type="fig"});                                                                                                                                                                                  
  Bronchoscopy (chronic inflammatory changes in bronchiolar mucosa);                                                                                                                                                                                                                                       
  X-ray imaging of the skull; CT scan of adrenal gland;                                                                                                                                                                                                                                                    
  X-ray imaging of long bones: (abnormally shallow hip socket that is suggestive of acetabular dysplasia or congenital hip dysplasia) (Figure [1](#F1){ref-type="fig"});                                                                                                                                   
  Liver biopsy (severe steatosis of hepatic cells with ballooning, lobular disarrays; mild changes, such as cholestasis, fibrosis, lymphocyte infiltration, Iron deposition, and bile duct proliferation);                                                                                                 
  Bone marrow aspirate (extreme proliferation of bone marrow cells with few hemophagocytic cells); peripheral blood smear                                                                                                                                                                                  
  Immunology                                                                                                                                                                                                                                                                                               Immunoglobulin levels (after IVIG therapy at local hospital): elevated IgG (20.2 g/L, normal range 3.7-8.3 g/L), IgM (1.47 g/L, normal range 0.33-1.25 g/L), and IgA (0.63 g/L, normal range 0.14-0.5) levels; normal IgE, complement 4, and complement 3 levels;
  Neutrophil oxidative burst activity, and lymphocyte subpopulations;                                                                                                                                                                                                                                      
  Autoimmune antibodies                                                                                                                                                                                                                                                                                    
  Biochemical, metabolic and endocrine profiling                                                                                                                                                                                                                                                           Glucose profiling (hypoglycemia); slightly elevated serum lactate (Table [1](#T1){ref-type="table"});
  Liver function test: cholestasis, hypoalbuminemia, abnormal blood coagulation profiles (Table [1](#T1){ref-type="table"});                                                                                                                                                                               
  Creatine kinase, lactate dehydrogenase;                                                                                                                                                                                                                                                                  
  Serum amino acids (proline 1803 μmol/L, normal range: 165-700 μmol/L; threonine 171 μmol/L, normal range: 17-90 μmol/L) and acyl-carnitine profile; urine organic acids (including succinylacetone); Urine acidoglycoprotein (51.98 mg/mmol creatinine, normal range: 59.70-78.52 mg/mmol creatinine).   
  Low levels of total serum cholesterol, HDL and LDL cholesterol (Table [1](#T1){ref-type="table"}).                                                                                                                                                                                                       
  Serum cortisol level; thyroid function test (total triiodothyronine 52.6 ng/dL, normal range: 70-220 ng/dL)                                                                                                                                                                                              
  Ophthalmology, electrocardiology, and echocardiogram (patent foramen ovale, 2.6 mm)                                                                                                                                                                                                                      
  Genetic disorders                                                                                                                                                                                                                                                                                        White blood cell lysosomal enzyme screening for GM1 gangliosidosis, GM2 gangliosidosis, Sandhoff disease, Krabbe leukodystrophy, Gaucher disease, Fabry disease, Pompe disease, metachromatic leukodystrophy, Nieman-Pick disease, neuronal ceroid lipofuscinoses (1 and 2), mucopolysaccharidosis (type I-VII, IX), muculipidosis (type II and III).
  Liver panel including 41 genes known to cause liver diseases, and trio whole exome sequencing (Table [2](#T2){ref-type="table"}).                                                                                                                                                                        

DISCUSSION
==========

MetRS is one of 20 ubiquitously expressed enzymes essential for protein biosynthesis, and covalently links methionine with its cognate tRNA. Since initial reports of *MARS* gene mutations causing ILLD\[[@B3]\] and CMT\[[@B6]\] in 2013, a total of 34 cases of ILLD\[[@B4],[@B5],[@B10]\] and eight cases of CMT\[[@B7]-[@B10]\] have been reported.

Similar to previous reports, the patient in our case showed a failure to thrive, developmental delay, interstitial lung disease, liver involvement (hepatomegaly, cholestasis, hepatic steatosis, fibrosis, and iron deposition), anemia, and thrombocytosis. An active proliferation of bone marrow cells has been reported by Sun et al\[[@B5]\]. Our patient had marked leukocytosis (white blood cell count up to 71.7 × 10^9^/L), and a bone marrow biopsy showed extreme proliferation of bone marrow cells with few hemophagocytic cells. MetRS is also a component of a cytoplasmic multiaminoacyl-tRNA synthetase complex with multiple roles in immune response, inflammation, and tumorigenesis\[[@B12],[@B13]\]. Prolonged low-grade fever, leukocytosis, thrombocytosis, and elevated c-reactive protein in this patient responded to intensive antibiotic treatment, and could be viewed as an exaggerated inflammatory or immune response to infection. Unlike previous reports of an arrest in red blood cell maturity\[[@B3],[@B5]\], a bone marrow biopsy from this patient showed marked proliferation of normal erythrocyte precursors.

While aminoaciduria has been reported\[[@B3]\], kidney stones have never been reported to be associated with a *MARS* mutation. No evidence of urinary tract infection, proteinuria, or organic aciduria was found in our case, and serum electrolytes with urea and creatinine were essentially normal. An evaluation of urinary citrate, calcium, and 24 h urine output in future ILLD cases might be necessary in order to rule out factors that promote renal stone formation\[[@B14]\]. Mutations in genes encoding mitochondrial seryl-tRNA synthetases have been reported to cause renal damage\[[@B15],[@B16]\], but no association of cytoplasmic aminoacyl-tRNA synthetases, including *MARS*, have been reported. Since previously reported mutations were all non-synonymous in nature, severe mutations (such as a truncation or single amino acid insertion as in our case) may have caused some renal impairment leading to stone formation.

No skeletal abnormality has been reported, with the exception of two ILLD cases with delayed bone age\[[@B5]\]. Our case had marked acetabular dysplasia consistent with developmental hip dysplasia. Other than being female, this infant did not have other risk factors\[[@B17]\], such as breach presentation upon delivery, local infection, or trauma. Whole exome sequencing did not reveal abnormalities in previously reported susceptible genes such as *GDF5*, *TBX4*, *ASPN*, *IL-6*, *TGF-b1*, and *PAPPA2*\[[@B18]\]. Hip dysplasia is associated with CMT\[[@B19]\], and the rate of hip dysplasia among children with CMT ranges from 6% to 8.1%\[[@B20]\]. Novarino et al\[[@B11]\] reported four cases of HSPs with compound heterozygous variants of the *MARS* gene in a family with infantile onset delayed motor milestones and disabilities upon crawling/walking. Two cases had bilateral Achilles contracture, one had scoliosis, but none had hip-joint abnormalities. A recent report of an ILLD case\[[@B10]\] with a p.Arg618Cys variant was also associated with CMT in a previous report\[[@B6]\], indicating ILLD and CMT may share a similar disease-causing mechanism. All reported cases of CMT, ILLD, and HSPs associated with the *MARS* gene had missense mutations. Our case had a truncating mutation and an insertion of a single amino acid. Severe mutations may have been responsible for the hip dysplasia, which could be an early manifestation of CMT in this patient.

The c.2158C\>T/p.Gln720Stop, which was inherited from the mother, caused the glutamine amino acid change at position 720, leading to a stop codon at a well-conserved α-helix bundle domain (anti-codon binding domain) of the methionyl-tRNA synthetase protein.

The tri-nucleotide insertion (c.893_894insTCG) with paternal origin caused the insertion of a single amino acid (arginine) at position 299 in the Rossmann fold domain (catalysis center). Nine out of 12 ILLD variants reported so far affected an amino acid in the Rossmann fold domain (Figure [2B](#F2){ref-type="fig"}). Arg299 is adjacent to the active methionine-binding site of human MetRS, which is surrounded by the amino acid residues Arg12, Leu13, Pro14, Thr257, Gly259, Tyr260, Asn297, and His301\[[@B21]\].

All eight mutations from European ILLD cases were located in the Rossmann fold of the MARS protein. However, only one out of four mutations from Chinese cases carried mutations in the Rossmann fold domain, and the location of mutations among Chinese ILLD cases was significantly different from that of European ILLD cases (Fisher\'s exact = 0.018) (Figure [2B](#F2){ref-type="fig"}). Our case also suggested that severe mutations may lead to more organ/system involvement and severe outcomes.

*In vivo* yeast complementation assays were used to predict the effects of *MARS* variants, including 1852C\>T/p.Arg618Cys\[[@B6]\], c.920A\>G/p.Tyr307Cys\[[@B10]\] and 1852C\>T/p.Arg618Cys\[[@B10]\]. The *in vitro* aminoacylation assay with HEK293 cells was used to confirm the effects of c.1108T\>C/p.Phe370Leu, and c.1568T\>C/p.Ile523Thr *MARS* variants\[[@B3]\]. The effects of c.1031A\>G/p.Tyr344Cys, c.1177G\>A/p.Ala393Thr, c.1700C\>T/p.Ser567Leu and c.1814A\>T/p.Asp605Val were studied using the *in vitro* yeast aminoacylation assay\[[@B4]\], and later by Comisso et al\[[@B22]\] using the *E. Coli*-based aminoacylation assay. Further functional studies are needed to confirm the effects of variants in our case, as well as variants reported by others (c.2398C\>A/p.Pro800Thr\[[@B7]\], c.433G\>A/p.Asp145Asn and c.2405T\>C/p.Phe802Ser\[[@B5]\]). Besides previously used methods, one may consider the use of animal models such as *Drosophila* and *C. elegans* to predict the pathogenicity of other aminoacyl-tRNA synthetase mutations\[[@B23]\].

There is currently no cure for ILLD, and thus treatment is only supportive. Provided that *in vitro* enzyme activity may partly be restored by increasing methionine\[[@B22]\], methionine supplementation could be considered in studies of animal models, or possibly even in humans. However, plasma levels of methionine and its toxic product homocysteine should be closely monitored.

In conclusion, truncation and insertion variants in the *MARS* gene may cause ILLD, and phenotypes of ILLD may also include kidney stones, acetabular dysplasia, prolonged fever, and extreme leukocytosis.

ARTICLE HIGHLIGHTS
==================

Case characteristics
--------------------

A five-month old female infant presented with failure to thrive, developmental delay, jaundice, and dark urine.

Clinical diagnosis
------------------

Typical clinical findings and whole exome sequencing results led to a diagnosis of interstitial lung and liver disease (ILLD).

Differential diagnosis
----------------------

Genetic cause was suspected due to multiple system involvement, but a liver panel consisting of 41 genes related to liver diseases came back negative. Lysosomal storage disease was considered, but an enzyme panel for screening common lysosomal storage diseases was normal, as was the urine acidoglycoprotein level.

Laboratory diagnosis
--------------------

Laboratory findings were Cholestasis, anemia, abnormal blood coagulation profiled, thrombocytosis, and extreme leukocytosis. Whole exome sequencing revealed a novel truncating variant (c.2158C\>T/p.Gln720Stop) and a novel tri-nucleotide insertion (c.893_894insTCG) in the methionyl-tRNA synthetase (*MARS*) gene.

Imaging diagnosis
-----------------

X-ray, computed tomography scan, and ultrasound imaging revealed interstitial lung disease, hepatomegaly, kidney stones, and acetabular dysplasia.

Pathological diagnosis
----------------------

Liver biopsy results showed severe hepatic steatosis, hepatic cells ballooning, lobular disarray, cholestasis, iron deposition, and mild fibrosis/lymphocyte infiltration/bile duct proliferation within the portal region.

Treatment
---------

Ursodeoxycholic acid, fat-soluble vitamins, antibiotics, oxygen therapy, and supportive treatment.

Related reports
---------------

Previous reports of ILLD were associated with biallelic missense mutations in the *MARS* gene. Phenotypes, such as kidney stones, acetabular dysplasia, prolonged fever, and extreme leukocytosis have never been reported to be associated with ILLD.

Term explanation
----------------

ILLD is interstitial lung and liver disease caused by homozygous or compound heterozygous mutations in the *MARS* gene. Typical findings in ILLD include failure to thrive, developmental delay, interstitial lung disease, liver involvement (hepatomegaly, cholestasis, hepatic steatosis, fibrosis, and iron deposition), anemia, and thrombocytosis.

Experiences and lessons
-----------------------

Regardless of race or ethnicity, ILLD should be considered in all patients with chronic liver diseases showing progressive interstitial lung involvement. Severe mutations may lead to more organ/system involvement and severe outcomes.
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